ESC Premium Access

Thromboembolic events and mortality in patients with atrial fibrillation and heart failure due to preserved versus reduced ejection fraction


About the speaker

Professor Eiichi Watanabe

Fujita Health University Second Hospital, Nagoya (Japan)
0 follower

24 more presentations in this session

Patients with atrial fibrillation treated with apixaban are less likely to discontinue study drug when compared with warfarin: insights from the ARISTOTLE trial

Speaker: Professor D. Xavier (Bangalore, IN)


Incidence of intracranial hemorrhage in the years 2013-15 in patients with atrial fibrillation in anticoagulant therapy: preliminary analysis of data from Ravenna registers

Speaker: Doctor C. Gatti (Ravenna, IT)


High SAMe-TT2R2 score, labile INR and major adverse outcomes in a real life cohort of anticoagulated patients with non-valvular atrial fibrillation

Speaker: Doctor D. Iglesias (Santiago de Compostela, ES)


CHA2DS2-Vasc score, as well as age and body mass index as the main risk factors of brain lesions in asymptomatic patients with paroxysmal non-valvular atrial fibrillation

Speaker: Doctor J. Wieczorek (Katowice, PL)


Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation

Speaker: Doctor A. Parwani (Berlin, DE)


Access the full session

Poster session 3 - Anticoagulation in atrial fibrillation III

Speakers: Professor E. Watanabe, Professor D. Xavier, Doctor C. Gatti, Doctor D. Iglesias, Doctor J. Wieczorek...

About the event



27 August - 31 August 2016

Sessions Presentations

This platform is supported by

logo Novo Nordisk